Prana's PBT434 Inhibits Accumulation of Parkinson's Protein and Subsequent
Death of Brain Cells.
New Data to Be Presented at the 11th International Conference on
Alzheimer's and Parkinson's Disease and the 11th International Basal
Ganglia Society Meeting in Eilat, Israel
MELBOURNE, AUSTRALIA -- (Marketwire) -- 03/06/13 -- Prana
Biotechnology (NASDAQ: PRAN) (ASX: PBT) today announced that PBT434,
Prana's lead drug candidate for Parkinson's Disease (PD) and movement
disorders, will be presented at two international conferences in
March. The key finding to be reported is that PBT434 reduces the
aggregation and accumulation of a key protein (alpha-synuclein) in
multiple transgenic animal models of the disease.
The alpha-synuclein (s.n.) protein aggregates inside the nerve cells
of the substantia nigra, the part of the brain that is progressively
damaged in the disease. The substantia nigra is responsible for
controlling movement. The (s.n.) protein aggregates are associated
with the onset and progression of Parkinson's Disease and in three
different Parkinson's Disease animal models, PBT434 significantly
prevented the death of substantia nigra brain cells.
"A treatment for Parkinson's Disease and other movement diseases that
actually modifies the course of the diseases remains a major unmet
medical need. Our data suggests that PBT434 intervenes in metal
dependent pathways which otherwise promote the aggregation of
alpha-synuclein. Thus, PBT434 prevents the death of substantia nigra
cells. We have observed marked improvements in motor function and
coordination with PBT434," commented Associate Professor Robert
Cherny, Prana's Head of Research.
Associate Professor David Finkelstein will present the new data at
the 11th International Basal Ganglia Society Meeting in Eilat,
Israel, March 3rd to 7th, 2013 in a talk titled "PD: Towards New
Disease Modifying Therapies."
In addition, Associate Prof Kevin Barnham will discuss PBT434 at the
11th International Conference on Alzheimer's and Parkinson's Disease,
to be held in Florence, Italy, March 6th to 10th, 2013. In a talk
titled "The Role of Nitrated Tau in PD."
PBT434 is being developed by Prana with support from the Michael J
Fox Foundation for Parkinson's Disease Research.
About Prana Biotechn
Prana Biotechnology was
established to commercialize research into age-related
neurodegenerative disorders. The Company was incorporated in 1997 and
listed on the Australian Securities Exchange in March 2000 and listed
on NASDAQ in September 2002. Researchers at prominent international
institutions including The University of Melbourne, The Mental Health
Research Institute (Melbourne) and Massachusetts General Hospital, a
teaching hospital of Harvard Medical School, contributed to the
discovery of Prana's technology.
For further information please visit the Company's web site at
About the New York Academy of Sciences
The New York Academy of
Sciences is an independent, not-for-profit organization committed to
advancing science, technology, and society worldwide since 1817. With
25,000 members in 140 countries, the Academy is creating a global
community of science for the benefit of humanity. The Academy's core
mission is to advance scientific knowledge, positively impact the
major global challenges of society with science-based solutions, and
increase the number of scientifically informed individuals in society
at large. Visit www.nyas.org for more information on the Academy.
Forward Looking Statements
This press release contains
"forward-looking statements" within the meaning of section 27A of the
Securities Act of 1933 and section 21E of the Securities Exchange Act
of 1934. The Company has tried to identify such forward-looking
statements by use of such words as "expects," "intends," "hopes,"
"anticipates," "believes," "could," "may," "evidences" and
"estimates," and other similar expressions, but these words are not
the exclusive means of identifying such statements. Such statements
include, but are not limited to any statements relating to the
Company's drug development program, including, but not limited to the
initiation, progress and outcomes of clinical trials of the Company's
drug development program, including, but not limited to, PBT2, and
any other statements that are not historical facts. Such statements
involve risks and uncertainties, including, but not limited to, those
risks and uncertainties relating to the difficulties or delays in
financing, development, testing, regulatory approval, production and
marketing of the Company's drug components, including, but not
limited to, PBT2, the ability of the Company to procure additional
future sources of financing, unexpected adverse side effects or
inadequate therapeutic efficacy of the Company's drug compounds,
including, but not limited to, PBT2, that could slow or prevent
products coming to market, the uncertainty of patent protection for
the Company's intellectual property or trade secrets, including, but
not limited to, the intellectual property relating to PBT2, and other
risks detailed from time to time in the filings the Company makes
with Securities and Exchange Commission including its annual reports
on Form 20-F and its reports on Form 6-K. Such statements are based
on management's current expectations, but actual results may differ
materially due to various factions including those risks and
uncertainties mentioned or referred to in this press release.
Accordingly, you should not rely on those forward-looking statements
as a prediction of actual future results.
+61 3 9349 4906
Press spacebar to pause and continue. Press esc to stop.